Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spectrum Pharmaceuticals, Inc. - Common Stock (NQ:SPPI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Spectrum Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Marathon Oil To Rally Around 65%? Plus This Analyst Cuts PT On Twilio By 55%
Raymond James raised the price target on Marathon Oil Corporation (NYSE: MRO) from $37 to $48. Raymond James analyst John Freeman maintained a Strong Buy rating on the stock. Marathon Oil shares fell... 
Via Benzinga
After FDA Rejection, Spectrum Shelves Development On Poziotinib
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Lufax Holding Shares Are Trading Lower By Over 11%; Here Are 21 Stocks Moving Premarket
Gainers VEON Ltd. (NASDAQ: VEON) shares rose 31.1% to $0.6095 in pre-market trading after the company agreed to sell its Russian business, Vimpelcom for 130 billion roubles ($2.2 billion). 
Via Benzinga
Expert Ratings for Spectrum Pharmaceuticals
Via Benzinga
Despite Regulatory Setback, Spectrum Still "Unique Investment Opportunity," Says Analyst
Via Benzinga
After Regulatory Setback, Spectrum Pharma Secures Up To $65M In Debt Funding
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Upgrades 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
FDA's Adcomm Gives Thumbs Down To Spectrum Pharmaceuticals' Lung Cancer Candidate
Via Benzinga
Earnings Scheduled For November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
Via Benzinga
Dow Hits New 2022 Low; Gold Falls Sharply
U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping to a fresh low for the year. 
Via Benzinga
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day... 
Via Benzinga
Nasdaq Tumbles Over 200 Points; Crude Oil Drops Sharply
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday. 
Via Benzinga
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're breaking down the biggest pre-market stock movers for Friday morning alongside the news that traders need to know about! 
Via InvestorPlace
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket
Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Genfit (NASDAQ:GNFT) shares increased by 27.4% to $5.12 during Thursday's after-market session. The market value of their outstanding shares is at $255.0 million. 
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Dow Dips 400 Points; Ford Shares Slide
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping 400 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million. 
Via Benzinga
Nasdaq Down 50 Points; Crude Oil Falls Sharply
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 50 points on Tuesday. 
Via Benzinga
Spectrum Plunges After FDA Casts Doubts On Its Lung Cancer Candidate
Ahead of an adcomm meeting for Spectrum Pharmaceutical Inc (NASDAQ: SPPI), FDA released briefing documents related to poziotinib for treating patients with previously treated locally advanced or... 
Via Benzinga
Looking Into Spectrum Pharmaceuticals's Recent Short Interest
Spectrum Pharmaceuticals's (NASDAQ:SPPI) short percent of float has risen 14.81% since its last report. The company recently reported that it has 4.05 million shares sold short,... 
Via Benzinga
What Is Going on With Spectrum Pharmaceuticals (SPPI) Stock Today?
Spectrum Pharmaceuticals received regulatory approval for its oncology-related infection-reducing therapeutic, bolstering SPPI stock. 
Via InvestorPlace
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.